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Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most frequent malignancy in Western countries [1] . The immunsuppression commonly accompanies other symptoms of disease. This phenomenon might be explained by i) increased level of immunosuppresive cytokine IL-10 [2] , ii) increased frequencies of T regulatory cells in B-CLL patients [3, 4] iii) decresed function of DC and T cells [5] and iv) hypogammaglobulinemia [6] . However some other mechanisms might be also involved in the escape of CLL cells from immunosurveillance. The expression of HLA-G was reported in certain malignancies and its role in escaping from immunosurveillance in cancers was proposed since HLA-G is a nonconventional HLA class I molecule expressed on trophoblast cells and therefore protecting fetus from immunorecognition during pregnancy [7] . Nuckel et al. [8] reported on the expression of HLA-G on CLL leukemic cells. Moreover it was concluded that HLA-G might constitute a novel prognostic factor superior to well established prognostic factors for patients with B-CLL such as Zeta-chain associated protein of 70kDa (ZAP-70) and CD38. In contrast Polakova et al. [9] in their comprehensive study on HLA-G in hematological malignancies described no expression of this protein on B-CLL cells. Recently, we compared two different staining techniques for the assessment of HLA-G molecule on protein level in B-CLL [10] . Both direct staining as well as non-direct staining were positive for CLL patients however it seemed that primary staining with pure anti-HLA-G antibody followed by staining with secondary antibody was more sensitive. To characterize the expression of HLA-G in B-CLL, in the current study the HLA-G protein was measured using flow cytometry analysis and HLA-G expression was confirmed on messenger RNA level by real-time RT-PCR.
fied advanced (stage 3 and 4). The expression of prognostic factors ZAP-70 and CD38 was assessed as described in details [11] . Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll (Biochrom, Germany) density gradient centrifugation. The viability of obtained PBMC was always >95%, as determined by trypan blue exclusion (Sigma-Aldrich, Germany). The viable cells were quantified in a Neubauer chamber (Zeiss, Germany) and stored for RNA preparation at -192°C in liquid nitrogen.
Flow cytometric analysis of cell surface antigens. The following FITC-, PE-and PerCP-conjugated monoclonal antibodies (moAb) were used for three colour flow cytometry analysis: anti-CD5PE (BD Biosciences,USA), anti-CD19 PerCP (BD Biosciences,USA). For moAb anti-HLA-G pure, clone MEM-G/9 (BD Pharmigen, USA) 10 6 cells were incubated for 20 min. at 4°C, thereafter washed and stained with secondary goat anti-mouse antibody conjugated with FITC (Dako, Denmark). In the following secondary staining cells were washed twice and stained with CD5 and CD19 for additional 15 minutes. Relevant isotype mouse controls were used. Before flow cytometric analysis, FACScalibur flow cytometer (BD Biosciences, USA) was calibrated. After immunofluorescence staining, cells were washed twice and 20.000 events were acquired and analysed using CellQuest software (BD Biosciences, USA). mRNA preparation and reverse transcription. For the isolation of mRNA from PBMC, the µMACS mRNA Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to the manufacturer's instructions. Briefly, after cell lysis, RNA was incubated with 50 µl Oligo (dT) Micro Beads (Miltenyi Biotec, Bergisch Gladbach, Germany) then isolated in the magnetic field through the MACS column Type µ (Miltenyi Biotec). After washing isolated mRNA was released from the column by pre-heated Elution Buffer (Miltenyi Biotec). The quality and quantity of the isolated mRNA was assessed using an Eppendorf BioPhotometer (Eppendorf, Hamburg, Germany). Fifty ng of mRNA was reverse transcribed into 20 µl of cDNA using a 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche Diagnostics, Mannheim, Germany). For each RT-PCR 1 µl of the cDNA preparation was used. Table 1 . Expression of HLA-G in patients with B-CLL (NA-not available).
cDNA was used per qRT-PCR. To quantify the mRNA expression of HLA-G, a conventional PCR for HLA-G from placenta was performed and the amount of product cDNA was measured by photometry using an Eppendorf BioPhotometer (Eppendorf). A serial dilution of cDNA was subjected to PCR to obtain standard curves. The amount obtained by quantitative measurement of mRNA in attogram (ag) for HLA-G and TBP was calculated into copy numbers and normalized against the house keeping gene TBP, of which hitherto no retro-pseudogenes are known.
Statistical analysis.
To compare HLA-G expression by groups of CLL patients, the non-parametric U Mann-Whitney test was used. Results lower than 0.01 were considered to be significant. Statistical analyses were performed using STATISTICA 5.1 (StatSoft, StatSoft Polska, Poland).
Results
The expression of HLA-G was detected in all CLL patients both on messenger RNA and protein level.
Using pure moAb, clone MEM-G/9 followed by secondary staining with goat antimouse moAb conjugated with fluorochrome, the median percentage of HLA-G expression in CLL cells was 7. Table 1 .
Discussion
HLA-G is a non-classical MHC molecule expressed in immune-priviledged areas where it plays an important role in the tolerance to fetal antigens. From 1998 when Paul et al. [12] for the first time described the expression of HLA-G in solid tumors, its re-expression during tumorigenesis is linked to suppress tumor recognition by immune system. Enhanced expression of HLA-G was found in several malignancies suggesting that HLA-G is involved in the escape of tumor cells from the immunosurveillance [7] . In this study the expression of HLA-G on both messenger and protein level was observed. Similar results were shown by Nuckel et al. [8] who found the expression of HLA-G in B-CLL on protein level and showed its prognostic properities for patients with B-CLL. In contrast Polakova et al. [9] found no expression of HLA-G on protein level using complex panel of monoclonal antibodies against HLA-G. On the other hand Amiot et al. [12] in comprehensive study on HLA-G expression in lymphoproliferative disorders showed the increased mRNA level of HLA-G. Interestingly enhanced expression of HLA-G mostly resulted in the increased serum levels of soluble HLA-G but hardly with increased expression as HLA molecule on cell surface. Amiot et al. [13] reported on the increased levels of soluble HLA-G (sHLA-G) in B-CLL patients. Augmented concentrations of sHLA-G might favor the progression of cancer by the inhibition of the function of T as well as NK cells [14] . It was suggested that HLA-G inhibits T cells and DC acts via ILT-2 (CD85j) and ILT4 (CD85d) [15, 16] . CLL cells express the HLA-G receptor ILT-2 [17] . The interaction between HLA-G tetramers with ILT-4 receptor on DC resulted in the reduced expression of HLA-DR [18] . Rebmann et al. [19] speculated whether the reduced expression of HLA-DR on B-CLL cells is attributed to the interaction of sHLA-G with the ILT-2 receptor on B-CLL cells. The discrepancy between the expression of HLA-G on mRNA and protein level observed in this study in CLL cells might indicate that a part of translated HLA-G is released as sHLA-G.
In the current study no correlation of HLA-G expression neither on protein nor on messenger level with well established prognostic factors for B-CLL ZAP-70 and CD38 was detected. Nuckel et al. [8] also didn't find any correlation between HLA-G and ZAP-70 and CD38, however they found that the increased levels of HLA-G (cut-off 23%) resulted in a significantly shorter time to progression suggesting that HLA-G might serve as a surrogate prognostic factor in CLL. In our study we could not confirm this relationship, possibly due to a limited number of patients.
In summary, our study revealed the expression of HLA-G in B-CLL on protein level and confirmed using real-time RT-PCR. The expression of HLA-G in B-CLL suggests that this molecule might represent an additional mechanism of tumor escape from the immunosurveillance.
